Exercise program for breast cancer patients undergoing chemotherapy
All-extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function During Chemotherapy for Breast Cancer
NA · University of Florida · NCT04914663
This study tests if a special exercise program can help breast cancer patients undergoing chemotherapy stay heart-healthy during their treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 68 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | Female |
| Sponsor | University of Florida (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Gainesville, Florida) |
| Trial ID | NCT04914663 on ClinicalTrials.gov |
What this trial studies
This research examines a novel exercise intervention aimed at breast cancer patients who are undergoing chemotherapy. The study focuses on whether this exercise program can help protect against cardiovascular dysfunction, which is a concern for many patients in this demographic. Participants will engage in structured exercise training while receiving their chemotherapy treatment, with the goal of improving their overall cardiovascular health. The findings could provide valuable insights into cardiovascular disease prevention for breast cancer survivors.
Who should consider this trial
Good fit: Ideal candidates are female patients aged 18 to 85 with a diagnosis of non-metastatic breast cancer who are scheduled to start chemotherapy.
Not a fit: Patients with significant cardiovascular diseases or those receiving concurrent targeted therapies or radiation therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could enhance cardiovascular health and overall well-being for breast cancer patients undergoing chemotherapy.
How similar studies have performed: Other studies have shown positive outcomes with exercise interventions in cancer patients, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III * Female * 18 to 85 years of age * Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane) * Absence of contraindications to exercise * Study clinician approval * Able to give consent * Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process Exclusion Criteria: * Do not meet inclusion criteria * Receiving targeted therapies (CDK4/6 or PARP inhibitors) * Receiving radiation therapy concurrent with chemotherapy * Lymphedema stage ≥ 2 prior to study enrollment * Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Where this trial is running
Gainesville, Florida
- Integrative Cardiovasculal Physiology Laboratory, University of Florida — Gainesville, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: Demetra Christou, PhD — University of Florida
- Study coordinator: Demetra Christou, PhD
- Email: ddchristou@ufl.edu
- Phone: 3522941746
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer